Whole brain radiotherapy for brain metastasis
Open Access
- 1 January 2013
- journal article
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 4 (5) , 236-44
Abstract
Whole brain radiotherapy (WBRT) is a mainstay of treatment in patients with both identifiable brain metastases and prophylaxis for microscopic disease. The use of WBRT has decreased somewhat in recent years due to both advances in radiation technology, allowing for a more localized delivery of radiation, and growing concerns regarding the late toxicity profile associated with WBRT. This has prompted the development of several recent and ongoing prospective studies designed to provide Level I evidence to guide optimal treatment approaches for patients with intracranial metastases. In addition to defining the role of WBRT in patients with brain metastases, identifying methods to improve WBRT is an active area of investigation, and can be classified into two general categories: Those designed to decrease the morbidity of WBRT, primarily by reducing late toxicity, and those designed to improve the efficacy of WBRT. Both of these areas of research show diversity and promise, and it seems feasible that in the near future, the efficacy/toxicity ratio may be improved, allowing for a more diverse clinical application of WBRT.Keywords
This publication has 88 references indexed in Scilit:
- Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trialNeuro-Oncology, 2013
- Current Dosing Paradigm for Stereotactic Radiosurgery Alone After Surgical Resection of Brain Metastases Needs to Be Optimized for Improved Local ControlInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastasesCochrane Database of Systematic Reviews, 2012
- Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)European Journal of Cancer, 2012
- Whole-brain irradiation with concomitant daily fixed-dose Temozolomide for brain metastases treatment: A randomised phase II trialRadiotherapy and Oncology, 2012
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- Radiation Somnolence SyndromeJournal of Pediatric Oncology Nursing, 2000
- Chemotherapy of brain metastases from lung carcinomaNeurosurgery, 1991
- Epidemiology of brain tumorsNeurology, 1985
- The morphologic effects of radiation administered therapeutically for intracranial gliomas.A Postmortem study of 25 casesCancer, 1979